fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models

被引:147
作者
Dudhani, Rajesh V. [1 ]
Turnidge, John D. [2 ,3 ,4 ,5 ]
Nation, Roger L. [1 ]
Li, Jian [1 ]
机构
[1] Monash Univ, Facil Antiinfect Drug Dev & Innovat Drug Delivery, Monash Inst Pharmaceut Sci, Melbourne, Vic 3004, Australia
[2] Womens & Childrens Hosp, Adelaide, SA, Australia
[3] Univ Adelaide, Dept Pathol, Adelaide, SA, Australia
[4] Univ Adelaide, Dept Paediat, Adelaide, SA, Australia
[5] Univ Adelaide, Dept Mol & Biomed Sci, Adelaide, SA, Australia
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
Gram-negative bacteria; emergence of resistance; population analysis profiles; heteroresistance; CRITICALLY-ILL PATIENTS; MULTIDRUG-RESISTANT; PSEUDOMONAS-AERUGINOSA; DISEASES-SOCIETY; BAD BUGS; METHANESULFONATE; PHARMACOKINETICS; HETERORESISTANCE; EMERGENCE; AMERICA;
D O I
10.1093/jac/dkq226
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To elucidate the pharmacokinetic/pharmacodynamic (PK/PD) index that predicts colistin efficacy against Acinetobacter baumannii in neutropenic murine thigh and lung infection models, and to determine the extent of the emergence of resistance in vivo to colistin. PK/PD of colistin was studied in thigh and lung infection models against A. baumannii ATCC 19606 and two multidrug-resistant clinical isolates (two of the three strains were colistin heteroresistant). Dose fractionation studies were conducted over a daily dose range of 1-160 mg/kg colistin sulphate. Bacterial burden in tissues was measured at 24 h. Non-linear least squares regression analyses were employed to determine the PK/PD index (fAUC/MIC, fC(max)/MIC or fT(> MIC)) best correlating with the efficacy of colistin in each model. Real-time population analysis profiles were conducted for tissue samples to monitor the emergence of resistance. The fAUC/MIC was the PK/PD index that correlated best with efficacy in both thigh (R(2) = 0.90) and lung (R(2) = 0.80) infection models. The fAUC/MIC targets required to achieve stasis and 1 log kill against the three strains were 1.89-7.41 and 6.98-13.6 in the thigh infection model, respectively, while the corresponding values were 1.57-6.52 and 8.18-42.1 in the lung infection model. Amplification of colistin-resistant subpopulations was revealed for all strains in both models after 24 h colistin treatment. This study indicates the importance of achieving adequate time-averaged exposure to colistin and defined target fAUC/MIC values for various magnitudes of kill. Amplification of resistant subpopulations indicates the importance of investigating rational combinations with colistin. The results will facilitate efforts to optimize colistin use in humans.
引用
收藏
页码:1984 / 1990
页数:7
相关论文
共 24 条
[11]   Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis [J].
Li, J ;
Coulthard, K ;
Milne, R ;
Nation, RL ;
Conway, S ;
Peckham, D ;
Etherington, C ;
Turnidge, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (06) :987-992
[12]   Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography [J].
Li, J ;
Milne, RW ;
Nation, RL ;
Turnidge, JD ;
Coulthard, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1364-1370
[13]   Antibiograms of multidrug-resistant clinical Acinetobacter baumannii:: Promising therapeutic options for treatment of infection with colistin-resistant strains [J].
Li, Jian ;
Nation, Roger L. ;
Owen, Roxanne J. ;
Wong, Stephanie ;
Spelman, Denis ;
Franklin, Clare .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (05) :594-598
[14]   Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii [J].
Li, Jian ;
Rayner, Craig R. ;
Nation, Roger L. ;
Owen, Roxanne J. ;
Spelman, Denis ;
Tan, Kar Eng ;
Liojios, Lisa .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) :2946-2950
[15]   Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study [J].
Markou, Nikolaos ;
Markantonis, Sophia L. ;
Dirnitrakis, Efthirnios ;
Panidis, Dimitris ;
Boutzouka, Eleni ;
Karatzas, Styllanos ;
Rafailidis, Petros ;
Apostolakos, Haralarnpos ;
Baltopoulos, George .
CLINICAL THERAPEUTICS, 2008, 30 (01) :143-151
[16]   Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates [J].
Mendes, Rodrigo E. ;
Fritsche, Thomas R. ;
Sader, Helio S. ;
Jones, Ronald N. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (08) :1324-1326
[17]   THE SERUM-PROTEIN BINDING OF VANCOMYCIN IN PATIENTS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS INFECTION - THE ROLE OF SERUM ALPHA(1)-ACID GLYCOPROTEIN LEVELS [J].
MORITA, K ;
YAMAJI, A .
THERAPEUTIC DRUG MONITORING, 1995, 17 (02) :107-112
[18]   Current concepts: Acinetobacter infection [J].
Munoz-Price, L. Silvia ;
Weinstein, Robert A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (12) :1271-1281
[19]   In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates [J].
Owen, Roxanne J. ;
Li, Jian ;
Nation, Roger L. ;
Spelman, Denis .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (03) :473-477
[20]   Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria [J].
Plachouras, D. ;
Karvanen, M. ;
Friberg, L. E. ;
Papadomichelakis, E. ;
Antoniadou, A. ;
Tsangaris, I. ;
Karaiskos, I. ;
Poulakou, G. ;
Kontopidou, F. ;
Armaganidis, A. ;
Cars, O. ;
Giamarellou, H. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) :3430-3436